Agnieszka Zielińska

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Peter Nash, Bruce Kirkham, Masato Okada et al. · The Lancet · 2017 · 405 citations · Full text

Medicine, Immunology, Pharmacotherapy +13

SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study

Adrian Shields, Sian Faustini, Marisol Pérez-Toledo et al. · Thorax · 2020 · 298 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +12

PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Expression

Kelly Chiang, Agnieszka Zielińska, Abeer M. Shaaban et al. · Cell Reports · 2017 · 204 citations · Full text

Medicine, Molecular Biology, Oncology +17

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy

Jung‐Yoon Choe, Nenad Prodanović, Jaroslaw Niebrzydowski et al. · Annals of the Rheumatic Diseases · 2015 · 166 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Phase <scp>III</scp> Randomized Study of <scp>SB</scp>5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis

Michael E. Weinblatt, Asta Baranauskaitė, Jaroslaw Niebrzydowski et al. · Arthritis & Rheumatology · 2017 · 133 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15